3 Oral Generics, Biotech Research Services and Fermentation APIs Stocks With a Strong Future Roadmap: Strides Pharma Science, Anthem Biosciences and Concord Biotech
- October 21, 2026
- Posted by: Lakshit Sharma
- Category: Best Stocks
Strides Pharma Science, Anthem Biosciences and Concord Biotech: ROE of 12.9% to 19.4% and FY22 to FY26 revenue CAGR of 10.7% to 15.5%. Prices as of 20 Oct 2026.
Quick Answer
The three biotech and generics stocks to watch are Strides Pharma Science, Anthem Biosciences and Concord Biotech. Their return on equity ranges from 12.9% to 19.4%, and their revenue compound annual growth from FY22 to FY26 ranges from 10.7% to 15.5%. Anthem Biosciences leads on both return on equity at 19.4% and revenue growth at 15.5% a year. Prices are based on the 20 October 2026 close, and this article is educational, not investment advice.
Biotech and generics stocks combine steady medicine demand with the technical skill needed for newer therapies. Strides Pharma Science, Anthem Biosciences and Concord Biotech cover a generics maker with oral and injectable products, a biotech research and manufacturing services company and a fermentation-based active ingredient producer.
This list covers three biotech and generics stocks with complete current figures: Strides Pharma Science, Anthem Biosciences and Concord Biotech. Every figure comes from the latest reported financials and the 20 October 2026 market close. Companies without complete current figures were left out.
Click Here – Get Free Investment Predictions
What Are Biotech and Generics Stocks?
Biotech and generics stocks are listed companies that make off-patent medicines, biologically derived ingredients or provide research and manufacturing services to drug developers. Their results depend on approvals, customer programmes and plant utilisation.
Biotech and Generics Stocks at a Glance
| Company | CMP (Rs) | Market Cap (Rs Cr) | P/E | Industry P/E | ROE (%) | D/E |
|---|---|---|---|---|---|---|
| Strides Pharma Science | 1,029.3 | 9,491 | 15.0 | 36.0 | 17.9 | 0.57 |
| Anthem Biosciences | 808.5 | 45,546 | 79.1 | 36.0 | 19.4 | 0.02 |
| Concord Biotech | 1,285.8 | 13,421 | 49.2 | 36.0 | 12.9 | 0.00 |
On valuation, Strides Pharma Science trades at a P/E below the industry P/E, while Anthem Biosciences and Concord Biotech trade above it, which reflects the growth the market already expects. Readers comparing biotech and generics stocks should look at return on equity and debt together, since a high return earned with low debt is easier to sustain.
Why Do Biotech and Generics Stocks Have a Strong Roadmap in India?
Biotech and generics stocks have a strong roadmap in India because global drug makers are widening their use of Indian partners for complex ingredients, research services and affordable generics.
- Complex manufacturing. Fermentation and biotech processes need skills that few suppliers have.
- Outsourcing trend. Drug developers hand more research and production work to specialist partners.
- Generic demand. Healthcare systems rely on generics to widen access to treatment.
Why Strides Pharma Science Features Among These Biotech and Generics Stocks
Among the biotech and generics stocks on this list, Strides Pharma Science, based in Bengaluru, makes finished dosage generics for the United States and other regulated markets, with oral solids and soft gel capsules as important product groups.
The company has a return on equity of 17.9%, a debt to equity ratio of 0.57 and a market capitalisation of Rs 9,491 crore. The stock trades at a P/E of 15.0, below the industry P/E of 36.0.
Revenue rose from Rs 3,202 crore in FY22 to Rs 5,009 crore in FY26, a compound annual growth rate of 11.8%. Net profit grew from Rs 409 crore in FY25 to Rs 575 crore in FY26, a rise of 40.3%. In the June 2026 quarter, revenue grew 12.6% year on year to Rs 1,270 crore, while net profit rose 56.7% to Rs 165 crore.
Roadmap: The company is leaning on new product launches in its regulated-market pipeline and improving utilisation of its plants. Profit can rise faster than revenue as volumes build on an existing cost base.
What to watch: Track new US launches and the pace of price erosion in generic categories.
Why Anthem Biosciences Features Among These Biotech and Generics Stocks
Among the biopharma shares on this list, Anthem Biosciences is a research-driven contract development and manufacturing organisation that serves global pharma and biotech customers with discovery, development and manufacturing services.
Revenue rose from Rs 1,280 crore in FY22 to Rs 2,280 crore in FY26, a compound annual growth rate of 15.5%. Net profit grew from Rs 406 crore in FY22 to Rs 592 crore in FY26, which works out to a compound annual growth rate of 9.9%.
The company has a return on equity of 19.4%, a debt to equity ratio of 0.02 and a market capitalisation of Rs 45,546 crore. The stock trades at a P/E of 79.1, above the industry P/E of 36.0.
Roadmap: The company offers an integrated platform from discovery to commercial manufacturing, which makes it a partner for innovator clients. Its biologics, peptides and small-molecule services give it several routes to growth.
What to watch: Monitor the order pipeline from global customers and the ramp-up of newer manufacturing capacity.
Why Concord Biotech Features Among These Biotech and Generics Stocks
Among the three companies on this list, Concord Biotech is a Gujarat-based biopharma company that makes fermentation-based active ingredients such as immunosuppressants, oncology drugs and anti-infectives for global pharma customers.
In the June 2026 quarter, revenue grew 24.2% year on year to Rs 270 crore, while net profit rose 31.0% to Rs 57.7 crore. Revenue rose from Rs 736 crore in FY22 to Rs 1,107 crore in FY26, a compound annual growth rate of 10.7%.
Net profit grew from Rs 175 crore in FY22 to Rs 259 crore in FY26, which works out to a compound annual growth rate of 10.3%. The company has a return on equity of 12.9%, a debt to equity ratio of 0.00 and a market capitalisation of Rs 13,421 crore. The stock trades at a P/E of 49.2, above the industry P/E of 36.0.
Roadmap: The company is among the leading global suppliers in its key immunosuppressant molecules and is moving into formulations and new fermentation products. Its backward integration and regulatory approvals support its position.
What to watch: Monitor the pace of new product introductions and the contribution from formulations.
Strides Pharma Science vs Anthem Biosciences vs Concord Biotech on Key Financials
The table below sets the three biotech and generics stocks side by side on revenue, profit and margin, using reported figures.
| Company | FY22 Revenue (Rs Cr) | FY26 Revenue (Rs Cr) | Revenue CAGR (FY22-FY26) | FY26 Net Profit (Rs Cr) | FY26 Net Margin |
|---|---|---|---|---|---|
| Strides Pharma Science | 3,202 | 5,009 | 11.8% | 575 | 11.5% |
| Anthem Biosciences | 1,280 | 2,280 | 15.5% | 592 | 26.0% |
| Concord Biotech | 736 | 1,107 | 10.7% | 259 | 23.4% |
Anthem Biosciences posts the highest return on equity in this group at 19.4%. Strides Pharma Science has the largest FY26 revenue at Rs 5,009 crore, and Anthem Biosciences shows the fastest revenue growth with a 15.5% compound annual rate. A useful habit with biotech and generics stocks is to check each new quarterly result against the capacity plans the company described earlier.
Key Risks to Check Before Investing in Biotech and Generics Stocks
Every theme carries risks that deserve a check before any decision. For these biotech and generics stocks, the main points are:
- Regulatory audits. Plant inspections can affect supply and approvals.
- Customer concentration. A few large customers can account for much of the revenue.
- Price erosion. Generic prices in regulated markets can change with competition.
Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.
Use the Univest Stock Screener to filter biotech and generics stocks by market capitalisation, P/E, ROE and growth, and build your own shortlist.
Final Thoughts on Biotech and Generics Stocks
Biotech and generics stocks suit investors who study customer relationships, approvals and capacity. Strides Pharma Science, Anthem Biosciences and Concord Biotech each bring a specialised capability to a growing market. Based on the 20 October 2026 close, Strides Pharma Science trades at Rs 1,029.3, Anthem Biosciences at Rs 808.5 and Concord Biotech at Rs 1,285.8.
Download the Univest iOS App or Univest Android App to track biotech and generics stocks, set price alerts and get research-backed stock ideas.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
What are biotech and generics stocks?
Ans. Biotech and generics stocks are listed companies that make off-patent medicines, biologically derived ingredients or provide research and manufacturing services to drug developers. Their results depend on approvals, customer programmes and plant utilisation. This list looks at three of them, Strides Pharma Science, Anthem Biosciences and Concord Biotech, using reported FY22 to FY26 financials and the 20 October 2026 closing prices.
Which biotech and generics stocks are covered in this list?
Ans. This list covers Strides Pharma Science, Anthem Biosciences and Concord Biotech. Based on the 20 October 2026 close, Strides Pharma Science traded at Rs 1,029.3, Anthem Biosciences at Rs 808.5 and Concord Biotech at Rs 1,285.8. Their return on equity ranges from 12.9% to 19.4%, and their revenue compound annual growth from FY22 to FY26 ranges from 10.7% to 15.5%.
Why do biotech and generics stocks have a strong future roadmap in India?
Ans. Biotech and generics stocks have a strong roadmap in India because global drug makers are widening their use of Indian partners for complex ingredients, research services and affordable generics. The main drivers are as follows. Complex manufacturing. Fermentation and biotech processes need skills that few suppliers have. Outsourcing trend. Drug developers hand more research and production work to specialist partners. Generic demand. Healthcare systems rely on generics to widen access to treatment. Together these factors give the companies on this list a visible path for growth over the coming years.
How has Strides Pharma Science performed financially?
Ans. Revenue rose from Rs 3,202 crore in FY22 to Rs 5,009 crore in FY26, a compound annual growth rate of 11.8%. Net profit grew from Rs 409 crore in FY25 to Rs 575 crore in FY26, a rise of 40.3%. In the June 2026 quarter, revenue grew 12.6% year on year to Rs 1,270 crore, while net profit rose 56.7% to Rs 165 crore. The company has a return on equity of 17.9%, a debt to equity ratio of 0.57 and a market capitalisation of Rs 9,491 crore. The stock trades at a P/E of 15.0, below the industry P/E of 36.0. Looking ahead, the company is leaning on new product launches in its regulated-market pipeline and improving utilisation of its plants. Profit can rise faster than revenue as volumes build on an existing cost base.
How has Anthem Biosciences performed financially?
Ans. Revenue rose from Rs 1,280 crore in FY22 to Rs 2,280 crore in FY26, a compound annual growth rate of 15.5%. Net profit grew from Rs 406 crore in FY22 to Rs 592 crore in FY26, which works out to a compound annual growth rate of 9.9%. The company has a return on equity of 19.4%, a debt to equity ratio of 0.02 and a market capitalisation of Rs 45,546 crore. The stock trades at a P/E of 79.1, above the industry P/E of 36.0. Looking ahead, the company offers an integrated platform from discovery to commercial manufacturing, which makes it a partner for innovator clients. Its biologics, peptides and small-molecule services give it several routes to growth.
How has Concord Biotech performed financially?
Ans. Revenue rose from Rs 736 crore in FY22 to Rs 1,107 crore in FY26, a compound annual growth rate of 10.7%. Net profit grew from Rs 175 crore in FY22 to Rs 259 crore in FY26, which works out to a compound annual growth rate of 10.3%. In the June 2026 quarter, revenue grew 24.2% year on year to Rs 270 crore, while net profit rose 31.0% to Rs 57.7 crore. The company has a return on equity of 12.9%, a debt to equity ratio of 0.00 and a market capitalisation of Rs 13,421 crore. The stock trades at a P/E of 49.2, above the industry P/E of 36.0. Looking ahead, the company is among the leading global suppliers in its key immunosuppressant molecules and is moving into formulations and new fermentation products. Its backward integration and regulatory approvals support its position.
What risks should investors check before buying biotech and generics stocks?
Ans. Investors should check a few risks before buying biotech and generics stocks. Regulatory audits. Plant inspections can affect supply and approvals. Customer concentration. A few large customers can account for much of the revenue. Price erosion. Generic prices in regulated markets can change with competition. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.
Is this list of biotech and generics stocks investment advice?
Ans. No. This article is educational and uses publicly available data as of the 20 October 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.